---
document_datetime: 2025-12-02 05:02:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kerendia.html
document_name: kerendia.html
version: success
processing_time: 0.0970387
conversion_datetime: 2025-12-27 20:23:48.188626
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kerendia

[RSS](/en/individual-human-medicine.xml/67521)

##### Authorised

This medicine is authorised for use in the European Union

finerenone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kerendia](#news-on)
- [More information on Kerendia](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Kerendia is a medicine used to treat chronic kidney disease in adults with type 2 diabetes.

It is used for patients with moderate or severe kidney damage who pass albumin (a type of protein) in their urine.

Kerendia contains the active substance finerenone.

Expand section

Collapse section

## How is Kerendia used?

Kerendia can only be obtained with a prescription.

Kerendia is available as tablets to be taken by mouth once a day. The dosage to be taken depends on the patient's kidney function.

For more information about using Kerendia, see the package leaflet or contact your doctor or pharmacist.

## How does Kerendia work?

The active substance in Kerendia, finerenone, binds to a receptor (target) known as mineralocorticoid receptor (MR). MR is involved in the activation of processes that cause inflammation and scarring in the kidneys. By binding to MR, Kerendia blocks the start of these processes, preventing inflammation and scarring and leading to less kidney damage.

## What benefits of Kerendia have been shown in studies?

Kerendia, in addition to standard treatment, was shown to be effective at slowing down kidney disease in one main study involving over 5,600 patients with chronic kidney disease and type 2 diabetes. In this study, 18% of patients taking Kerendia (504 out of 2,833) experienced a loss of kidney function compared with 21% of patients taking a placebo, or dummy treatment, (600 out of 2,841).

## What are the risks associated with Kerendia?

The most common side effect with Kerendia (which may affect more than 1 in 10 people) is the presence of high potassium levels in the blood. Other common side effects, which may affect up to 1 in 10 people, are low levels of sodium in the blood, low blood pressure, itching and loss of kidney function.

Kerendia must not be used in patients with Addison's disease (a condition that prevents the body from producing enough of the hormones cortisol and aldosterone). It must also not be used with certain medicines that strongly block the effects of CYP3A4, a liver enzyme that helps the body process many medicines.

For the full list of side effects and restrictions of Kerendia, see the package leaflet.

## Why is Kerendia authorised in the EU?

Kerendia was shown to slow down loss of kidney function in adults with chronic kidney disease and type 2 diabetes. Overall, the medicine's side effects were considered manageable. Therefore, the European Medicines Agency decided that Kerendia's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Kerendia?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kerendia have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Kerendia are continuously monitored. Side effects reported with Kerendia are carefully evaluated and any necessary action taken to protect patients.

## Other information about Kerendia

Kerendia received a marketing authorisation valid throughout the EU on 16 February 2022.

Kerendia : EPAR - Medicine Overview

Reference Number: EMEA/H/C/005200

English (EN) (119.39 KB - PDF)

**First published:** 11/03/2022

[View](/en/documents/overview/kerendia-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-694)

български (BG) (142.88 KB - PDF)

**First published:**

11/03/2022

[View](/bg/documents/overview/kerendia-epar-medicine-overview_bg.pdf)

español (ES) (118.08 KB - PDF)

**First published:**

11/03/2022

[View](/es/documents/overview/kerendia-epar-medicine-overview_es.pdf)

čeština (CS) (140.62 KB - PDF)

**First published:**

11/03/2022

[View](/cs/documents/overview/kerendia-epar-medicine-overview_cs.pdf)

dansk (DA) (116.16 KB - PDF)

**First published:**

11/03/2022

[View](/da/documents/overview/kerendia-epar-medicine-overview_da.pdf)

Deutsch (DE) (117.88 KB - PDF)

**First published:**

11/03/2022

[View](/de/documents/overview/kerendia-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.08 KB - PDF)

**First published:**

11/03/2022

[View](/et/documents/overview/kerendia-epar-medicine-overview_et.pdf)

ελληνικά (EL) (141.39 KB - PDF)

**First published:**

11/03/2022

[View](/el/documents/overview/kerendia-epar-medicine-overview_el.pdf)

français (FR) (117.81 KB - PDF)

**First published:**

11/03/2022

[View](/fr/documents/overview/kerendia-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.08 KB - PDF)

**First published:**

11/03/2022

[View](/hr/documents/overview/kerendia-epar-medicine-overview_hr.pdf)

italiano (IT) (115.44 KB - PDF)

**First published:**

11/03/2022

[View](/it/documents/overview/kerendia-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (147.46 KB - PDF)

**First published:**

11/03/2022

[View](/lv/documents/overview/kerendia-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.11 KB - PDF)

**First published:**

11/03/2022

[View](/lt/documents/overview/kerendia-epar-medicine-overview_lt.pdf)

magyar (HU) (138.9 KB - PDF)

**First published:**

11/03/2022

[View](/hu/documents/overview/kerendia-epar-medicine-overview_hu.pdf)

Malti (MT) (140.82 KB - PDF)

**First published:**

11/03/2022

[View](/mt/documents/overview/kerendia-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.09 KB - PDF)

**First published:**

11/03/2022

[View](/nl/documents/overview/kerendia-epar-medicine-overview_nl.pdf)

polski (PL) (141.98 KB - PDF)

**First published:**

11/03/2022

[View](/pl/documents/overview/kerendia-epar-medicine-overview_pl.pdf)

português (PT) (118.35 KB - PDF)

**First published:**

11/03/2022

[View](/pt/documents/overview/kerendia-epar-medicine-overview_pt.pdf)

română (RO) (135.9 KB - PDF)

**First published:**

11/03/2022

[View](/ro/documents/overview/kerendia-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.06 KB - PDF)

**First published:**

11/03/2022

[View](/sk/documents/overview/kerendia-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.14 KB - PDF)

**First published:**

11/03/2022

[View](/sl/documents/overview/kerendia-epar-medicine-overview_sl.pdf)

Suomi (FI) (114.33 KB - PDF)

**First published:**

11/03/2022

[View](/fi/documents/overview/kerendia-epar-medicine-overview_fi.pdf)

svenska (SV) (115.69 KB - PDF)

**First published:**

11/03/2022

[View](/sv/documents/overview/kerendia-epar-medicine-overview_sv.pdf)

Kerendia : EPAR - Risk management plan summary

English (EN) (118.66 KB - PDF)

**First published:** 11/03/2022

**Last updated:** 20/03/2023

[View](/en/documents/rmp-summary/kerendia-epar-risk-management-plan-summary_en.pdf)

## Product information

Kerendia : EPAR - Product Information

English (EN) (776.58 KB - PDF)

**First published:** 11/03/2022

**Last updated:** 17/09/2024

[View](/en/documents/product-information/kerendia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-118)

български (BG) (890.13 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/bg/documents/product-information/kerendia-epar-product-information_bg.pdf)

español (ES) (766.17 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/es/documents/product-information/kerendia-epar-product-information_es.pdf)

čeština (CS) (895.54 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/cs/documents/product-information/kerendia-epar-product-information_cs.pdf)

dansk (DA) (705.2 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/da/documents/product-information/kerendia-epar-product-information_da.pdf)

Deutsch (DE) (800.72 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/de/documents/product-information/kerendia-epar-product-information_de.pdf)

eesti keel (ET) (725.46 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/et/documents/product-information/kerendia-epar-product-information_et.pdf)

ελληνικά (EL) (830.83 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/el/documents/product-information/kerendia-epar-product-information_el.pdf)

français (FR) (836.02 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/fr/documents/product-information/kerendia-epar-product-information_fr.pdf)

hrvatski (HR) (856.57 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/hr/documents/product-information/kerendia-epar-product-information_hr.pdf)

íslenska (IS) (758.06 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/is/documents/product-information/kerendia-epar-product-information_is.pdf)

italiano (IT) (747.01 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/it/documents/product-information/kerendia-epar-product-information_it.pdf)

latviešu valoda (LV) (855.09 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/lv/documents/product-information/kerendia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (783.3 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/lt/documents/product-information/kerendia-epar-product-information_lt.pdf)

magyar (HU) (810.91 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/hu/documents/product-information/kerendia-epar-product-information_hu.pdf)

Malti (MT) (840.94 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/mt/documents/product-information/kerendia-epar-product-information_mt.pdf)

Nederlands (NL) (759.8 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/nl/documents/product-information/kerendia-epar-product-information_nl.pdf)

norsk (NO) (726.43 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/no/documents/product-information/kerendia-epar-product-information_no.pdf)

polski (PL) (887.72 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/pl/documents/product-information/kerendia-epar-product-information_pl.pdf)

português (PT) (787.34 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/pt/documents/product-information/kerendia-epar-product-information_pt.pdf)

română (RO) (853.92 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/ro/documents/product-information/kerendia-epar-product-information_ro.pdf)

slovenčina (SK) (873.69 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/sk/documents/product-information/kerendia-epar-product-information_sk.pdf)

slovenščina (SL) (873.93 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/sl/documents/product-information/kerendia-epar-product-information_sl.pdf)

Suomi (FI) (788.89 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/fi/documents/product-information/kerendia-epar-product-information_fi.pdf)

svenska (SV) (735.99 KB - PDF)

**First published:**

11/03/2022

**Last updated:**

17/09/2024

[View](/sv/documents/product-information/kerendia-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0009 16/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kerendia : EPAR - All authorised presentations

English (EN) (53.89 KB - PDF)

**First published:** 11/03/2022

[View](/en/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-170)

български (BG) (77.04 KB - PDF)

**First published:**

11/03/2022

[View](/bg/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_bg.pdf)

español (ES) (54.73 KB - PDF)

**First published:**

11/03/2022

[View](/es/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (64.25 KB - PDF)

**First published:**

11/03/2022

[View](/cs/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (57.21 KB - PDF)

**First published:**

11/03/2022

[View](/da/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (56.46 KB - PDF)

**First published:**

11/03/2022

[View](/de/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (57.12 KB - PDF)

**First published:**

11/03/2022

[View](/et/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (74.51 KB - PDF)

**First published:**

11/03/2022

[View](/el/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_el.pdf)

français (FR) (56.64 KB - PDF)

**First published:**

11/03/2022

[View](/fr/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (75.68 KB - PDF)

**First published:**

11/03/2022

[View](/hr/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (57.41 KB - PDF)

**First published:**

11/03/2022

[View](/is/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (55.97 KB - PDF)

**First published:**

11/03/2022

[View](/it/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (75.35 KB - PDF)

**First published:**

11/03/2022

[View](/lv/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (76.16 KB - PDF)

**First published:**

11/03/2022

[View](/lt/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (76.38 KB - PDF)

**First published:**

11/03/2022

[View](/hu/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (75.62 KB - PDF)

**First published:**

11/03/2022

[View](/mt/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (55.71 KB - PDF)

**First published:**

11/03/2022

[View](/nl/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (76.77 KB - PDF)

**First published:**

11/03/2022

[View](/no/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_no.pdf)

polski (PL) (67.75 KB - PDF)

**First published:**

11/03/2022

[View](/pl/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_pl.pdf)

português (PT) (57.36 KB - PDF)

**First published:**

11/03/2022

[View](/pt/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_pt.pdf)

română (RO) (72.58 KB - PDF)

**First published:**

11/03/2022

[View](/ro/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (76.61 KB - PDF)

**First published:**

11/03/2022

[View](/sk/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (76.01 KB - PDF)

**First published:**

11/03/2022

[View](/sl/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (56.7 KB - PDF)

**First published:**

11/03/2022

[View](/fi/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (55.62 KB - PDF)

**First published:**

11/03/2022

[View](/sv/documents/all-authorised-presentations/kerendia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kerendia Active substance Finerenone International non-proprietary name (INN) or common name finerenone Therapeutic area (MeSH)

- Renal Insufficiency, Chronic
- Diabetes Mellitus, Type 2

Anatomical therapeutic chemical (ATC) code C09

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Kerendia is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.

For study results with respect to renal and cardiovascular events, see section 5.1.

## Authorisation details

EMA product number EMEA/H/C/005200

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Bayer AG

51368 Leverkusen

Opinion adopted 16/12/2021 Marketing authorisation issued 16/02/2022 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kerendia : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (113.1 KB - PDF)

**First published:** 20/02/2023

**Last updated:** 17/09/2024

[View](/en/documents/procedural-steps-after/kerendia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kerendia : H-C-5200-II-0001-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/41550/2023

English (EN) (12.85 MB - PDF)

**First published:** 20/02/2023

[View](/en/documents/variation-report/kerendia-h-c-5200-ii-0001-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Kerendia (II-01-G)

Adopted

Reference Number: EMA/CHMP/904661/2022

English (EN) (98.98 KB - PDF)

**First published:** 16/12/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kerendia-ii-01-g_en.pdf)

## Initial marketing authorisation documents

Kerendia : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/78746/2022

English (EN) (4.99 MB - PDF)

**First published:** 11/03/2022

[View](/en/documents/assessment-report/kerendia-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Kerendia

Adopted

Reference Number: EMA/CHMP/610605/2021

English (EN) (140.85 KB - PDF)

**First published:** 17/12/2021

[View](/en/documents/smop-initial/chmp-summary-opinion-kerendia_en.pdf)

#### News on Kerendia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022) 16/12/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021) 17/12/2021

#### More information on Kerendia

- [EMEA-001623-PIP01-14-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001623-pip01-14-m06)
- [An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People with Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000231)

**This page was last updated on** 17/09/2024

## Share this page

[Back to top](#main-content)